Shop by Category

Bioconjugate Drug Development & Manufacturing

CellMosaic offers a complete drug discovery and development program for drug conjugates and drug modifications using classical linkers and polymers. Over the years, CellMosaic has delivered many high-quality conjugate drugs for customers based on our advanced conjugation processes. These processes can be modified for new conjugate drug development for our customers.

 The services we provide include:

  • Custom design and development of conjugation strategies to fit your needs (customer owns the rights for the compound)
  • Proof-of-concept Studies: CellMosaic has in-house conjugation processes ready to quickly synthesize any drug conjugates for initial proof-of-concept studies.
  • Conjugate Drug Discovery:
    • Evaluation of the labeling sites
    • Evaluation of the linkage or labeling chemistry (stable vs. cleavable)
    • Evaluation of the linkers or polymers
  • Conjugate Drug Development:
    • Stability studies
    • Development of purification method for drug bioconjugates
    • Development of bio-analytical methods (HIC, SEC, cation or anion exchange HPLC, MS)
    • pK studies of conjugate drugs in blood and tissue extracts
    • Lipid formulation studies
    • Process development
    • Process transfer

Examples of Classical Drug Conjugates and Drug Modifications frequently done at CellMosaic:

Depending on the needs of a customer’s project, the typical turn-around time for synthesizing any drug conjugates for initial proof-of-concept is 6-8 weeks. Please contact us to discuss your project.

AqueaTether™ Therapeutics, a separate division of CellMosaic, has developed novel super-hydrophilic and high-loading AqueaTether™ linkers and polymers for drug conjugation. To explore this opportunity and learn more about AqueaTether™ platform technologies, please visit our website at

  • Oligo Based Drug Conjugate Example 1: Delivery of antisense oligonucleotides using poly lysine peptide (oligo-peptide conjugate)

    Oligo Based Drug Conjugate

    CellMosaic® offers bioconjugation research and development services for biopharmaceutical companies devoted to antisense and siRNA-based therapeutics. Some of the obstacles to developing oligonucleotide analogs and siRNA-based therapeutics include...

  • Depiction of complex drug conjugates involving three or more types of molecules Example 1: Preparation of Protein-mAb(AF647)4.5 and Peptide-mAb(AF647)4.5 conjugates.

    Other Drug Conjugates

    At CellMosaic®, we go the extra mile to take care of customers' projects. We have done many exploratory, challenging, and unconventional drug conjugation projects for our customers. Examples of unconventional drug conjugates made at...

  • Depiction of Drug labeled Peptide Example 1: Single label by design: a peptide-antibiotic conjugate

    Peptide-Drug Conjugate

    CellMosaic® has a lot of experience and expertise in preparing peptide or peptidomimetic-based drug conjugates. We help our customers develop peptide labeling/conjugation strategies, synthesize the modified peptide, perform the drug conjugation, and...

  • Depiction of drug molecules attached to a polymer Example 1: Loading hydrophobic drugs onto a hydrophilic polymer

    Polymer-Drug Conjugate

    As an alternative to the years of hard work and luck nescessary to obtain a highly selective small molecule drug, a delivery system properly tailored to carrying potent antitumor drugs can be used. In the mid-1970s, Ringsdorf, a polymer chemist, proposed...

  • Protein-Drug Conjugate Example 1: Synthesis of a protein-drug conjugate

    Protein-Drug Conjugate

    CellMosaic® offers research and development services for bio-pharmaceutical companies that develop recombinant proteins as therapeutics. New target-specific protein drugs can be developed by conjugating drugs or toxins to recombinant proteins. We can...